Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A group of autosomal recessive lysosomal storage disorders marked by the accumulation of gangliosides. They are caused by impaired enzymes or defective cofactors required for normal ganglioside degradation in the lysosomes. Gangliosidoses are classified by the specific ganglioside accumulated in the defective degradation pathway.
Biomarker and diagnostic research for gangliosidosis has been reported in the published literature.
14 clinical trials registered, 6 recruiting. Interventions under study include drug therapy, other interventions, biologic therapy, and procedural interventions. Pipeline includes 2 PHASE3, 2 PHASE2, 4 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07054515](https://clinicaltrials.gov/study/NCT07054515) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 11:54 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis |
PHASE3 |
Azafaros B.V. |
RECRUITING |
[NCT03333200](https://clinicaltrials.gov/study/NCT03333200) | Longitudinal Study of Neurodegenerative Disorders | — | University of Pittsburgh | RECRUITING |
[NCT03952637](https://clinicaltrials.gov/study/NCT03952637) | A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis | PHASE1 | National Human Genome Research Institute (NHGRI) | RECRUITING |
[NCT03047369](https://clinicaltrials.gov/study/NCT03047369) | The Myelin Disorders Biorepository Project | — | Children's Hospital of Philadelphia | RECRUITING |
[NCT07399704](https://clinicaltrials.gov/study/NCT07399704) | A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease | PHASE2 | Azafaros B.V. | RECRUITING |
105 publications have been identified in PubMed for gangliosidosis. Research spans Basic Science / Preclinical (33%), Case Report / Case Series (17%), and Gene Therapy / Novel Therapeutics (14%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 35 | 33% |
Patient case studies | 18 | 17% |
New treatment approaches | 15 | 14% |
Disease patterns and progression | 14 | 13% |
Testing and diagnosis research | 11 | 10% |
Clinical study results | 6 | 6% |
Other research | 3 | 3% |
Research summaries | 3 | 3% |
Pandit A (2026). [PMID: 42022979](https://pubmed.ncbi.nlm.nih.gov/42022979/). *Clin Case Rep*. [Case Report / Case Series]
Srivastava P (2026). [PMID: 41732653](https://pubmed.ncbi.nlm.nih.gov/41732653/). *Cureus*. [Case Report / Case Series]
Lu ES (2026). [PMID: 42137175](https://pubmed.ncbi.nlm.nih.gov/42137175/). *J Vitreoretin Dis*. [Case Report / Case Series]
Steiner MA (2026). [PMID: 42157966](https://pubmed.ncbi.nlm.nih.gov/42157966/). *Mol Ther Adv*. [Gene Therapy / Novel Therapeutics]
Fiori L (2026). [PMID: 41800148](https://pubmed.ncbi.nlm.nih.gov/41800148/). *JIMD reports*. [Diagnostic / Biomarker]
Jubran L (2026). [PMID: 41899173](https://pubmed.ncbi.nlm.nih.gov/41899173/). *J Clin Med*. [Basic Science / Preclinical]
Nishi E (2026). [PMID: 41479428](https://pubmed.ncbi.nlm.nih.gov/41479428/). *Clinical case reports*. [Gene Therapy / Novel Therapeutics]
Khalilian S (2026). [PMID: 40172712](https://pubmed.ncbi.nlm.nih.gov/40172712/). *Biochemical genetics*. [Epidemiology / Natural History]
Vyas M (2026). [PMID: 41977517](https://pubmed.ncbi.nlm.nih.gov/41977517/). *Int J Mol Sci*. [Other]
Tang JH (2026). [PMID: 41664471](https://pubmed.ncbi.nlm.nih.gov/41664471/). *Bioconjugate chemistry*. [Case Report / Case Series]